Antihormonal medicine removed in Australia will remain available in New Zealand

AstraZeneca has confirmed that the medication Goserelin will continue to be supplied to the New Zealand market despite its recent withdrawal from Australia. The company clarified that the decision to pull the drug from Australian pharmacies was unrelated to any concerns regarding the treatment's safety profile or its clinical effectiveness. Patients in New Zealand can expect consistent access to the antihormonal therapy moving forward. Health authorities have not indicated any changes to the drug's regulatory status in other regions. This development ensures that the supply chain for this specific medical treatment remains stable for neighboring populations.

The clarification prevents unnecessary alarm among patients regarding the safety of a widely used medical treatment.